Mayo Clinic Laboratories > Gastroenterology > Liver disease

Liver disease

Integrated testing to identify the underlying cause and risk for disease progression

With metabolic, viral, genetic, autoimmune, and malignant causes, liver disease affects individuals of all ages and with varied medical histories. Our comprehensive liver disease test menu was developed in collaboration with clinical experts and spans the array of liver disorders. Delivering end-to-end testing in one laboratory location, our evaluations provide clinicians with results that identify underlying causes and guide disease management.

1.5 billion

1.5 billion individuals globally affected by liver disease1

80M–100M

80M–100M people live with nonalcoholic fatty liver disease (NAFLD)2

25%

25% of patients with NAFLD go on to develop nonalcoholic steatohepatitis (NASH)3

Autoimmune liver disease Autoimmune liver disease
Autoimmune liver disease

Our comprehensive panel detects and quantifies antimitochondrial antibodies using an enzyme immunoassay and smooth muscle antibodies by indirect immunofluorescence assay with mouse stomach/kidney substrate.

Genetic liver disease Genetic liver disease
Genetic liver disease

Including testing for A1A deficiency, cholestasis, hemochromatosis, and Wilson disease, our genetic liver disease testing provides clarity on genetic causes to help direct patient care and disease management.

Hepatocellular carcinoma Hepatocellular carcinoma
Hepatocellular carcinoma

Our panel approach to hepatocellular carcinoma involves evaluating for several biomarkers associated with disease progression.

Metabolic liver disease Metabolic liver disease
Metabolic liver disease

We offer a robust menu of biomarker testing to assess liver disease related to nonalcoholic and alcoholic causes, including FibroTest-ActiTest, NASH-FibroTest, and direct alcohol biomarker testing.

Viral hepatitis Viral hepatitis
Viral hepatitis

Including evaluations for detection, confirmation, and quantification, as well as genotyping, our comprehensive viral hepatitis testing was developed by a collaborative team of physicians and laboratorians and uses an algorithmic approach to optimize test utilization.

News and updates

The latest

Targeted panel boosts accuracy of hereditary pancreatitis testing: Linda Hasadsri, M.D., Ph.D., and Huong T. Cabral, M.S., C.G.C.

Linda Hasadsri, M.D., Ph.D., and Huong T. Cabral, M.S., C.G.C., explain how Mayo Clinic Laboratories' targeted test panel facilitates accurate diagnosis of hereditary pancreatitis, which heightens the risk for pancreatic cancer. Test results can guide cancer monitoring for patients and their families.

Learn more
Tests aid diagnosis of primary biliary cholangitis: Anne Tebo, Ph.D.

Anne Tebo, Ph.D., explains how Mayo Clinic Laboratories' new serum tests help overcome the challenges of diagnosing primary biliary cholangitis, or PBC. Test results can guide clinical care for patients with this life-threatening autoimmune liver disease.

Assay finds genetic cause of low bile flow: Devin Oglesbee, Ph.D.

Devin Oglesbee, Ph.D., explains how Mayo Clinic Laboratories' cholestasis gene panel identifies mutations that cause low flow of bile from the liver. Test results help guide treatment decisions that can prevent liver damage.

Updated assay guides diagnosis of autoimmune liver disease: Anne Tebo, Ph.D.

Anne Tebo, Ph.D., explains how Mayo Clinic Laboratories' updated ALDG2 assay helps with the evaluation of patients with suspected autoimmune liver disease. The panel also helps with the evaluation of liver disease of unknown etiology.

Direct Ethanol Biomarker Testing: PETH

Paul Jannetto, Ph.D., describes Mayo Clinic Laboratories' new direct biomarker test for alcohol consumption. PETH is a blood test with a window of detection of about two to four weeks — compared with five days for urine-based screening for alcohol use.

Hepatitis C Virus Genotypic Antiviral Drug Resistance [Test in Focus]

Joseph Yao, M.D., gives an overview of this new test available through Mayo Clinic Laboratories. He discusses when this testing should be ordered, how this testing improves upon other testing approaches, and what clinical action can be taken due to the results of this testing.

Nonalcoholic Steatohepatitis (NASH)-FibroTest [Test in Focus]

Nikola Baumann, Ph.D., gives an overview of the new NASH-FibroTest available through Mayo Clinic Laboratories. She discusses when this testing should be ordered, how this testing improves upon previous testing approaches, and what clinical action can be taken due to the results of this testing.

Mayo Clinic Laboratory and Pathology Research Roundup: May 7

This week’s Research Roundup highlights how fasting blood-glucose levels provide estimate of duration and progression of pancreatic cancer before diagnosis.

Resources
View chart The full spectrum of liver disease testing
References
  1. Marcellin P, Kutala BK. Liver diseases: A major, neglected global public health problem requiring urgent actions and large-scale screening. Liver Int. 2018 Feb;38(Suppl 1):2-6.
  2. Perumpail BJ, Khan MA, Yoo ER, et al. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease. World J Gastroenterol. 2017 Dec;23(47):8263-8276.
  3. Peng C, Stewart AG, Woodman OL, Ritchie RH, Qin CX. Non-alcoholic steatohepatitis: a review of its mechanism, models and medical treatments. Front Pharmacol. 2020;11:603926. Published 2020 Dec 3. doi:10.3389/fphar.2020.603926
INTERESTED IN LEARNING MORE?

Fill out the form below and one of our specialists will be in touch.